Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 56 peer-reviewed journal articles Updated
Endocrinology

Lipodystrophy due to peptidic growth factors deficiency (including SHORT syndrome): A Patient Guide

At a Glance

SHORT syndrome is a rare genetic signaling disorder caused by changes in the PIK3R1 gene that can affect growth, fat distribution, and insulin response. Lifelong follow-up with endocrine, eye, and dental specialists helps monitor metabolic and developmental health.

Lipodystrophy due to peptidic growth factors deficiency is a medical classification describing rare genetic conditions that change how your body develops, grows, and manages energy. Unlike many growth-related conditions that stem from the body not making enough hormones, this condition is a “signaling” problem: the body produces the necessary growth factors, but the cells themselves process those signals inefficiently [1][2]. This breakdown in cellular communication is most commonly seen in SHORT syndrome, which is caused by pathogenic variants in the PIK3R1 gene [3]. Because the cells have an altered response to instructions from vital proteins like insulin and IGF-1, the condition affects multiple systems at once, leading to a combination of physical features and metabolic challenges [4].

One of the most visible effects of this signaling defect is partial lipoatrophy, a specific pattern of fat loss that typically affects the face, arms, and legs [5]. In this condition, “fat” is not just about weight or appearance; it is a vital metabolic organ. When fat tissue cannot develop or function correctly, the body struggles to manage sugar, leading to a risk of severe insulin resistance [6]. Interestingly, while many other forms of lipodystrophy cause dangerous fat buildup in the liver or blood, this specific signaling disorder may be less prominent in the liver, though liver and lipid issues can still occur and require monitoring [7][8].

What this diagnosis does NOT mean:

  • It is not caused by poor nutrition or parenting.
  • Not every person has the same features.
  • A normal glucose or triglyceride result does not eliminate the need for follow-up.

Living with this condition requires a proactive, lifelong partnership with a specialized medical team. Because the PI3K signaling pathway affects everything from bone growth and dental development to the internal structures of the eye, management extends far beyond blood sugar control [9][10]. Specialists in endocrinology, ophthalmology, and dentistry work together to monitor growth velocity, screen for eye pressure issues like glaucoma, and support dental health [4]. While there is currently no way to repair the underlying cellular signaling “wiring,” a coordinated care plan allows families to manage symptoms effectively and protect long-term metabolic health [11].

In this guide

6 chapters

01

Understanding Growth Factor Signaling and Lipodystrophy

Learn how growth-factor signaling relates to lipodystrophy and PIK3R1-related SHORT syndrome, including fat loss, insulin resistance, features, and follow-up.

02

The Cellular Signal: How PIK3R1 Mutations Affect Your Body

Learn how PIK3R1 mutations disrupt PI3K-AKT signaling in PIK3R1-related lipodystrophy, affecting insulin response, partial fat loss, and glucose control.

03

The Physical and Metabolic Signs of SHORT Syndrome

Learn the physical and metabolic signs of SHORT syndrome, including growth, lipoatrophy, insulin resistance, eye findings, dental delay, and diabetes risk.

04

Connecting the Clues: How the Diagnosis is Made

Learn how SHORT syndrome is diagnosed using growth and body-fat patterns, metabolic tests, and PIK3R1 genetic testing, including what a VUS result means.

05

Managing SHORT Syndrome: A Specialized Care Plan

Learn how to manage SHORT syndrome with blood-sugar monitoring, medication choices, growth hormone decisions, nutrition, and eye, dental, and heart screening.

06

Ongoing Monitoring and Staying Safe

Learn how SHORT syndrome is monitored safely, including blood sugar, eye, dental, heart, and hearing checks, urgent warning signs, and daily care plans.

Common questions in this guide

What is SHORT syndrome, and how is it related to this lipodystrophy?
SHORT syndrome is a rare genetic disorder in which cells respond inefficiently to growth-factor and insulin signals. It is the condition most commonly associated with this form of lipodystrophy and is caused by disease-causing changes in the PIK3R1 gene. The altered signaling can affect growth, fat distribution, and metabolism.
Why can SHORT syndrome cause fat loss and insulin resistance?
The signaling problem can prevent fat tissue from developing or working normally, especially in the face, arms, and legs. Because fat tissue helps the body manage blood sugar, abnormal or reduced fat tissue can make cells respond poorly to insulin.
Do normal glucose or triglyceride results mean follow-up is no longer needed?
No. Normal glucose or triglyceride results do not eliminate the need for follow-up because insulin resistance, liver or lipid problems, and other effects may develop or change over time. The care team can decide which metabolic and other checks are needed over time.
Which specialists should be involved in care?
Care commonly involves endocrinology, ophthalmology, and dentistry. These specialists can work together to monitor growth, metabolic health, eye pressure, and dental development. Ask which clinician will coordinate the team and how often each area should be reviewed.
Did poor nutrition or parenting cause this condition?
No. The condition is caused by a genetic signaling problem and is not caused by poor nutrition or parenting. Your care team can explain the gene variant identified in your case.
Can the underlying signaling problem be repaired?
There is currently no way to repair the underlying cellular signaling problem. However, coordinated lifelong care can manage symptoms, monitor metabolic and developmental health, and help protect long-term well-being.

Get notified when new evidence is published on Lipodystrophy due to peptidic growth factors deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (11)
  1. 1

    KBTBD2 controls bone development by regulating IGF-1 signaling during osteoblast differentiation.

    Xun Y, Jiang Y, Khalid A, et al.

    Cell death and differentiation 2025; (32(6)):1099-1111 doi:10.1038/s41418-024-01416-0.

    PMID: 39562829
  2. 2

    PI3-kinase mutation linked to insulin and growth factor resistance in vivo.

    Winnay JN, Solheim MH, Dirice E, et al.

    The Journal of clinical investigation 2016; (126(4)):1401-12.

    PMID: 26974159
  3. 3

    New classification and diagnostic criteria for insulin resistance syndrome.

    Ogawa W, Araki E, Ishigaki Y, et al.

    Endocrine journal 2022; (69(2)):107-113 doi:10.1507/endocrj.EJ21-0725.

    PMID: 35110500
  4. 4

    Clinical reappraisal of SHORT syndrome with PIK3R1 mutations: toward recommendation for molecular testing and management.

    Avila M, Dyment DA, Sagen JV, et al.

    Clinical genetics 2016; (89(4)):501-506 doi:10.1111/cge.12688.

    PMID: 26497935
  5. 5

    SHORT syndrome in a two-year-old girl - case report.

    Klatka M, Rysz I, Kozyra K, et al.

    Italian journal of pediatrics 2017; (43(1)):44 doi:10.1186/s13052-017-0362-z.

    PMID: 28472977
  6. 6

    Metformin paradoxically worsens insulin resistance in SHORT syndrome.

    Lewandowski KC, Dąbrowska K, Brzozowska M, et al.

    Diabetology & metabolic syndrome 2019; (11()):81 doi:10.1186/s13098-019-0477-z.

    PMID: 31583022
  7. 7

    Insulin resistance uncoupled from dyslipidemia due to C-terminal PIK3R1 mutations.

    Huang-Doran I, Tomlinson P, Payne F, et al.

    JCI insight 2016; (1(17)):e88766.

    PMID: 27766312
  8. 8

    Metreleptin In SHORT Syndrome With Uncontrolled Diabetes.

    Korakas E, Kountouri A, Ikonomidis I, et al.

    JCEM case reports 2025; (3(11)):luaf218 doi:10.1210/jcemcr/luaf218.

    PMID: 41080980
  9. 9

    SHORT Syndrome: Systematic Appraisal of the Medical and Dental Phenotype.

    Mubeen S, Gibson C, Mubeen R, et al.

    The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association 2022; (59(7)):873-881 doi:10.1177/10556656211026859.

    PMID: 34212753
  10. 10

    Iris Malformation and Anterior Segment Dysgenesis in Mice and Humans With a Mutation in PI 3-Kinase.

    Solheim MH, Clermont AC, Winnay JN, et al.

    Investigative ophthalmology & visual science 2017; (58(7)):3100-3106 doi:10.1167/iovs.16-21347.

    PMID: 28632845
  11. 11

    Clinical Guidelines for the Diagnosis and Management of Generalized and Partial Lipodystrophies: A Position Statement Endorsed by the Hellenic Endocrine Society.

    Lambadiari V, Bargiota A, Kanaka-Gantenbein C, et al.

    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2026; (32(6)):1008-1016 doi:10.1016/j.eprac.2026.02.014.

    PMID: 41713690

This page is for informational purposes only and does not constitute medical advice. Your endocrinology, eye, and dental care teams can interpret genetic, metabolic, growth, and examination findings for your specific situation.